MedTrace Logo

Sevoflurane for Treatment-Resistant Depression

NCT05008939 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-08-17

No results posted yet for this study

Summary

This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.

Conditions

  • Depressive Disorder, Treatment-Resistant
  • Depressive Disorder, Major

Interventions

DRUG

Sevoflurane

Patients receive 1% sevoflurane and 30% oxygen for 1 hour.

DRUG

Placebo

Patients received 30% oxygen for 1 hour.

Sponsors & Collaborators

  • Shanghai Pudong New Area Mental Health Center

    collaborator UNKNOWN

  • Shanghai First Maternity and Infant Hospital

    lead OTHER

Principal Investigators

  • Zhiqiang Liu, MD · Department of Anesthesiaology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05008939 on ClinicalTrials.gov